26.90
-0.74(-2.68%)
Currency In USD
| Previous Close | 27.64 |
| Open | 26.99 |
| Day High | 27.96 |
| Day Low | 26.51 |
| 52-Week High | 30.6 |
| 52-Week Low | 2.76 |
| Volume | 1.28M |
| Average Volume | 2.94M |
| Market Cap | 2.81B |
| PE | -12.51 |
| EPS | -2.15 |
| Moving Average 50 Days | 23.3 |
| Moving Average 200 Days | 9.55 |
| Change | -0.74 |
If you invested $1000 in Alumis Inc. Common Stock (ALMS) since IPO date, it would be worth $2,022.56 as of March 09, 2026 at a share price of $26.9. Whereas If you bought $1000 worth of Alumis Inc. Common Stock (ALMS) shares 1 year ago, it would be worth $2,022.56 as of March 09, 2026 at a share price of $26.9.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Alumis to Present at the Leerink Partners Global Healthcare Conference
GlobeNewswire Inc.
Mar 02, 2026 1:05 PM GMT
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Martin Babler,
Alumis to Participate in Upcoming February Investor Conferences
GlobeNewswire Inc.
Feb 05, 2026 1:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company wil
Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire Inc.
Jan 09, 2026 9:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the clos